Press Releases

Date Title
Toggle Summary Kura Oncology Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
SAN DIEGO , Dec. 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of
Toggle Summary Kura Oncology to Participate in the JMP Securities Hematology Summit
SAN DIEGO , Dec. 10, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology Summit.
Toggle Summary Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock
SAN DIEGO , Dec. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 8,110,000 shares of
Toggle Summary Kura Oncology Announces Commencement of Public Offering of Common Stock
SAN DIEGO , Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to
Toggle Summary Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 at American Society of Hematology Annual Meeting
– Evidence of biologic activity observed in each dose-escalation cohort treated to date – – Clinical activity includes one CR in a patient with a NPM1 mutation and one CR in a patient with a SETD2/RUNX1 mutation – – Continuous daily dosing well tolerated and with manageable safety profile to date –
Toggle Summary Kura Oncology to Host Virtual Investor Event on December 5, 2020
Event to follow presentation of preliminary clinical data for menin inhibitor KO-539 at ASH SAN DIEGO , Nov. 24, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of
Toggle Summary Kura Oncology Reports Third Quarter 2020 Financial Results
– Preliminary data from first-in-human trial of menin inhibitor KO-539 accepted for oral presentation at ASH – – Encouraging safety, tolerability and activity with KO-539 highlighted in ASH abstract – – Preclinical data support expansion opportunity for tipifarnib plus PI3Kα inhibitor in HRAS-
Toggle Summary Kura Oncology to Participate in Three Upcoming Investor Conferences
SAN DIEGO , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three upcoming virtual
Toggle Summary Kura Oncology to Report Third Quarter 2020 Financial Results
SAN DIEGO , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report third quarter 2020 financial results before the open of
Toggle Summary Kura Oncology Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Kα Inhibitor in Head and Neck Squamous Cell Carcinoma
– Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of HNSCC – – Company plans to conduct a Phase 1/2 proof-of-concept study of tipifarnib in combination with a PI3Kα inhibitor in relapsed/refractory HNSCC – SAN DIEGO